This voice is automatically generated. Please let us know if you have one. feedback.
All blockbuster drugs have to start somewhere. Behind the best-selling drugs on Big Pharma’s income statements are products that may not have generated significant sales yet, but have grown significantly early in their lifecycles.
Merck & Co.’s cancer giant Keytruda has the pneumococcal vaccine VaxNuvance. J&J’s long-time immunology blockbuster Stelara has racked up billions of dollars in sales, but its growth rate pales in comparison to oncology newcomer Techvayly. Although these products are not yet well-known, this one-year improvement of his is superior to other products from the pharmaceutical giant.
With the potential for high sales, these new treatments could become critical as once blockbuster drugs approach the patent cliff in the coming years.
Of course, some of the most advanced newcomers have already made a huge impact on the pharmaceutical industry, such as Novo Nordisk and Eli Lilly’s diabetes and weight-loss drugs. Less than two years after their release, these treatments have taken the pharmaceutical industry by storm and are expected to establish themselves as tent poles in the future. They are currently limited only by their nascent manufacturing capacity as companies scramble to meet surging demand.
These are the most improved products in each of the world’s 10 largest pharmaceutical companies by market capitalization during the year, as reported in their first quarter results.
David Ricks, Eli Lilly CEO
Permission by Eli Lilly
Eli Lilly – Munjaro
2024 Q1 revenue: $1.8 billion
First quarter 2023 revenue: $569 million
Growth rate: 218%*
*Calculated by PharmaVoice. Lilly did not report Munjaro’s growth rate during this period.
GLP-1 diabetes and weight loss drug Mounjaro, launched in June 2022, was so in demand that its own success has hampered its earnings More than double On a year-over-year basis, the drug still fell short of analysts’ expectations due to supply issues related to manufacturing capacity. However, like Lilly’s other GLP-1 Zepbound, this treatment marks a new wave of further growth for Lilly. Strengthen your supply chainas CEO David Rix promised on the earnings call.
Novo Nordisk – Wegovy
Sales in the first quarter of 2024: DKK 9.4 billion ($1.4 billion)
Sales in the first quarter of 2023: DKK 4.6 billion ($665 million)
Growth rate: 106%
Novo Nordisk, along with Eli Lilly, is changing the diabetes and weight loss landscape with two GLP-1 treatments: Ozempic and Wigovy. In the first quarter, Ozempic had better overall sales performance, but Wegovy showed even more growth. Sales will double Throughout the year.And its momentum shows no signs of slowing down – the company report At least 25,000 patients in the U.S. use Wegovy each week, four times more than last December.
Johnson & Johnson – Tekvayli
First quarter 2024 sales: $133 million
Revenue for Q1 2023: $63 million
Growth rate: 111%*
*Calculated by PharmaVoice. J&J did not report growth rates for the period, citing the numbers as “more than 100% or meaningless.”
Tekvaili was the first bispecific T cell engager approved In the United States, it is targeted at patients with multiple myeloma.Sales of more than Double from 2023 to 2024 A full year after the drug hit the market, Jennifer Torbert, J&J’s head of innovative medicines, called the franchise the company’s “home base.” The results also demonstrated the need for new treatments in the difficult-to-treat area of multiple myeloma.
Not far behind Tekvayli in terms of year-on-year growth is Supravat, an esketamine drug used to treat depression. The “party drug,” which went through a rigorous regulatory process before being approved in 2019, saw annual sales increase 72.2% to $225 million.
Merck & Co. – Vac Neuvence
First quarter 2024 sales: $219 million
Revenue for Q1 2023: $106 million
Growth rate: 106%
Merck, known for its blockbuster cancer drug Keytruda and HPV prevention drug Gardasil, is climbing the charts with another vaccine.Vac Neuvence Approved in 2021 competes with Pfizer’s Prevnar franchise to prevent illnesses caused by pneumococci in children; Sales doubled Year after year, key The pediatric adaptation gave Merck an advantage in entering this field.
AbbVie – Crypta
First quarter 2024 net revenue: $131 million
Q1 2023 Net Revenue: $66 million
Growth rate: 97.7%
AbbVie’s rheumatoid arthritis drug Humira has long been a cash cow for Big Pharma, but as biosimilar sales begin to decline, investors are looking for new drugs to fill the void. Although the migraine drug Qulipta is still in its early stages, Revenue almost doubled The past year has shown that the migraine market may finally be starting to see some penetration.a New FDA indication Last year, the market for oral anti-CGRP drugs expanded for patients with episodic and chronic migraines, contributing to revenue growth.
And as AbbVie looks to maintain its pole position in the rheumatoid arthritis market, next-generation Humira analog Rinvoke is showing signs of improvement, with year-over-year growth of nearly 60%.
AstraZeneca – Safnero
Q1 2024 revenue: $91 million
Q1 2023 revenue: $47 million
Growth rate: 94%
The lupus drug Safnero, approved in 2021, changed the way the medical community approaches lupus. long misunderstood autoimmune condition. AstraZeneca has powerfully entered a market with many unmet needs by directly addressing the immune system rather than standard off-label treatments.and it is paid by Revenue almost doubled About drugs in the past year.
AstraZeneca also saw sales of its breast cancer drug Enherz increase 79% to $461 million. This drug was developed in collaboration with Japan’s Daiichi Sankyo. collect new signs The partners hope it will be a long journey to develop the market’s potential.
Novartis – Lecvio
First quarter 2024 net sales: $151 million
Q1 2023 Net Sales: $64 million
Growth rate: 136%
The cholesterol drug Leqvio is long term results Treatments just twice a year have been shown to reduce the risk of heart disease and stroke. Given the high unmet need for cholesterol treatments around the world, Novartis quickly saw a promising future in this treatment. 136% growth After just a few years on the market, year-over-year sales have increased.
Novartis’ most improved drug last year was its multiple sclerosis drug Kesimpta, which saw sales rise 66% to $637 million in the first quarter of this year.
Roche/Genentech – Vabysmo
Sales in the first quarter of 2024: CHF 847 million ($933 million)
Sales in the first quarter of 2023: CHF 432 million ($476 million)
Growth rate: 108%
Babismo, a drug for treating eye diseases more than doubled Its sales were strong despite competition from long-dominant Regeneron and Bayer’s Eylea. Sales of the drug, which beat analysts’ expectations, still lag Eyrie’s sales, but strong growth last year shows Roche’s Genentech is closing the gap in the ophthalmology field.
Amgen – Evenity
First quarter 2024 sales: $342 million
Revenue for Q1 2023: $254 million
Growth rate: 35%
Amgen’s bone drug Evenity, approved in 2019, is the successor to the company’s best-selling Prolia, which has seen slowing growth. biosimilar Enter the market. Like AbbVie’s Rinvoke, Evenity aims to improve on his predecessor’s performance and keep Amgen at the top of the postmenopausal bone density market. Although Evenity has not yet reached his Prolia sales figures, 35% growth This shows that the company still fills an unmet need and provides Amgen with runway in the therapeutic space.
Pfizer – Bindakel family
2024 Q1 revenue: $1.1 billion
First quarter 2023 revenue: $686 million
Growth rate: 66%
Pfizer’s Vyndaquel, Vindamax, and Vinmac have been one of the saving graces for the pharmaceutical giant in the post-pandemic years.Amid a decline in overall revenue due to soaring prices for new coronavirus vaccines, the impact of nerve-damaging drugs exceeded $1 billion The quarter saw 66% year-over-year growth. The market for the Vindakel franchise as a rare disease drug is not deep, but competitors such as Alnylam have struggled to push Pfizer’s brand off the market. their cloak.
